Almac Increase Global Stability Storage Capacity
News Nov 05, 2013
Almac have completed a $2m investment programme which doubles its global API and drug product stability storage capacity in line with its growth forecast.
Almac’s new storage capacity at both its European headquarters in Craigavon, UK, and at its USA headquarters in Souderton, PA enable conditions of 25°C / 60% RH, 30°C / 65% RH, 30°C / 75% RH, 40°C / 75% RH, 5°C, -20°C to be offered.
All conditions are ICH compliant, continually monitored, and supported (?) with back-up systems ensuring a totally secure and controlled environment.
Within its Analytical Services unit, ICH method development, validation, dissolution and release testing are also offered. This capability enables physical and chemical stability studies to be conducted on both API and a diverse range of drug products, including DEA controlled substances.
Rick Dyer, VP Quality Operations, commented, “With over 150 live stability programmes being managed at any one time, this is a welcome investment and enhancement to our facilities in both UK and USA. Coupled with the recent completion of our API manufacturing facility, Almac are well placed to support the development and regulatory approval of our clients’ drug development programmes.”
Aeri Park, Director of USA Operations, added, “The brand new stability chambers are of the highest quality standards to continue offering excellent reliability and increased efficiency for our clients looking to outsource stand alone stability studies, or in an integrated fashion, with Almac’s clinical trial supply services.”
Almac can provide stability studies from a single batch to multiple batches / packaging materials for both drug substance and drug product; from non-GMP compliance to pivotal registration / commercial studies.
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE